Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimers Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
NIA will soon fund research to validate new drug targets and discover early-stage therapies for Alzheimer's and related dementias, focusing on preclinical studies for novel treatments.
Funder: National Institutes of Health
Due Dates (Anticipated): October 2026 (Full application deadline, projected)
Funding Amounts: Award size not yet specified; funding instrument is Cooperative Agreement (U01); duration and total program funding to be announced.
Summary: Supports preclinical validation and early-stage drug discovery for novel therapeutic targets in Alzheimer's disease and related dementias.
Key Information: This is a forecasted opportunity; application details and funding specifics will be available in the official NOFO.
Description
The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), intends to issue a Notice of Funding Opportunity (NOFO) for research focused on Alzheimer's disease (AD) and AD-related dementias (ADRD). This program will support rigorous preclinical validation of novel drug targets and early-stage drug discovery, including small molecules, biologics, and emerging therapeutic modalities. The opportunity is designed to accelerate the development of new treatments and prevention strategies for AD/ADRD by advancing promising candidate targets through the preclinical pipeline.
This forecasted opportunity uses the U01 Cooperative Agreement mechanism and is intended for investigators with expertise in AD/ADRD research and drug discovery. The notice is provided in advance to allow researchers time to develop collaborations and responsive projects.
